MDGL

#806
Madrigal Pharmaceuticals, Inc. - Common Stock
543.6 9 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
543.69
543.69
Jahresspanne
393.61
614.36
Tagesänderung
+0.89%
Monatliche Änderung
+0.39%
6 month change
+26.37%
Jahresänderung
+28.35%
Vorheriger Schlusskurs
538.8 8
Open
543.6 9
Tief
543.6 9
Hoch
543.6 9
Volumen
65
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
MADRIGAL PHARMACEUTICALS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
MADRIGAL PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
MADRIGAL PHARMACEUTICALS, INC. annual report, FY2025
10-K

MADRIGAL PHARMACEUTICALS, INC. current report, Q1 FY2022

Full document

Business Context and Reporting Period

Company: Madrigal Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 24, 2022
Reporting Period: Fourth fiscal quarter and fiscal year ended December 31, 2021.

This filing serves to announce the issuance of a press release containing the Company's financial results for the specified period. The detailed financial data is contained within Exhibit 99.1 (Press Release) and is incorporated by reference.

Key Financial Metrics

The provided text is a cover sheet for the 8-K filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the accompanying press release (Exhibit 99.1) but are not present in the source text provided.

Material Changes

The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the fourth quarter and full year 2021 have been announced.

Guidance, Outlook, and Risks

Management Commentary: The filing references a press release issued on February 24, 2022, which contains the Company's financial results and likely includes management commentary, though the text of that commentary is not included in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover sheet. The filing includes a standard disclaimer stating that the information in this report and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release Dated February 24, 2022) for specific revenue, net loss, and cash position figures.
  • Verify the Company's cash runway and burn rate as disclosed in the full press release.
  • Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
  • Confirm if the Company provided updated financial guidance for 2022 in the referenced press release.

Nachrichten